KZIA
Price:
$0.3715
Market Cap:
$17.82M
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.[Read more]
Industry
Biotechnology
IPO Date
1999-01-06
Stock Exchange
NASDAQ
Ticker
KZIA
According to Kazia Therapeutics Limited’s latest financial reports and current stock price. The company's current Enterprise Value is 14.62M. This represents a change of -72.90% compared to the average of 53.95M of the last 4 quarters.
The mean historical Enterprise Value of Kazia Therapeutics Limited over the last ten years is 172.54M. The current 14.62M Enterprise Value has changed 747.29% with respect to the historical average. Over the past ten years (40 quarters), KZIA's Enterprise Value was at its highest in in the September 2021 quarter at 2.05B. The Enterprise Value was at its lowest in in the June 2017 quarter at 8.14M.
Average
172.54M
Median
20.43M
Minimum
5.38M
Maximum
1.52B
Discovering the peaks and valleys of Kazia Therapeutics Limited Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 5.50%
Maximum Annual Enterprise Value = 1.52B
Minimum Annual Increase = -95.06%
Minimum Annual Enterprise Value = 5.38M
Year | Enterprise Value | Change |
---|---|---|
2023 | 28.28M | -62.33% |
2022 | 75.06M | -95.06% |
2021 | 1.52B | 5.50% |
2020 | 27.11M | 67.43% |
2019 | 16.19M | 20.26% |
2018 | 13.46M | 81.28% |
2017 | 7.43M | -21.87% |
2016 | 9.50M | 76.57% |
2015 | 5.38M | -78.17% |
2014 | 24.66M | 27.88% |
The current Enterprise Value of Kazia Therapeutics Limited (KZIA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
540.55M
5-year avg
332.99M
10-year avg
172.54M
Kazia Therapeutics Limited’s Enterprise Value is less than CytomX Therapeutics, Inc. (62.24M), less than Assembly Biosciences, Inc. (90.35M), less than Ocular Therapeutix, Inc. (923.38M), greater than Spero Therapeutics, Inc. (12.49M), greater than Achilles Therapeutics plc (-61068820.00), less than SELLAS Life Sciences Group, Inc. (68.00M), greater than NLS Pharmaceutics AG (6.83M), less than Mereo BioPharma Group plc (582.99M), greater than Aravive, Inc. (-3158140.00), less than Day One Biopharmaceuticals, Inc. (1.01B), less than ZIVO Bioscience, Inc. (37.60M), greater than RenovoRx, Inc. (12.72M), greater than Pasithea Therapeutics Corp. (-3592870.00), greater than Quoin Pharmaceuticals, Ltd. (218.65K), greater than ARCA biopharma, Inc. (1.56M), greater than Bionomics Limited (-1949260.00), less than OKYO Pharma Limited (36.16M), less than Candel Therapeutics, Inc. (194.11M), less than Anebulo Pharmaceuticals, Inc. (41.53M), greater than Cingulate Inc. (12.85M), less than Nurix Therapeutics, Inc. (1.41B), less than Seer, Inc. (95.89M), less than Quantum-Si incorporated (71.78M), less than HCW Biologics Inc. (35.48M), less than MediciNova, Inc. (59.15M),
Company | Enterprise Value | Market cap |
---|---|---|
62.24M | $93.74M | |
90.35M | $107.81M | |
923.38M | $1.31B | |
12.49M | $71.07M | |
-61068820.00 | $29.58M | |
68.00M | $76.56M | |
6.83M | $6.09M | |
582.99M | $664.26M | |
-3158140.00 | $2.95M | |
1.01B | $1.25B | |
37.60M | $37.03M | |
12.72M | $24.47M | |
-3592870.00 | $4.37M | |
218.65K | $3.06M | |
1.56M | $34.82M | |
-1949260.00 | $8.81M | |
36.16M | $36.16M | |
194.11M | $197.00M | |
41.53M | $46.68M | |
12.85M | $12.55M | |
1.41B | $1.50B | |
95.89M | $100.74M | |
71.78M | $129.66M | |
35.48M | $26.62M | |
59.15M | $103.00M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kazia Therapeutics Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Kazia Therapeutics Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Kazia Therapeutics Limited's Enterprise Value?
What is the highest Enterprise Value for Kazia Therapeutics Limited (KZIA)?
What is the 3-year average Enterprise Value for Kazia Therapeutics Limited (KZIA)?
What is the 5-year average Enterprise Value for Kazia Therapeutics Limited (KZIA)?
How does the current Enterprise Value for Kazia Therapeutics Limited (KZIA) compare to its historical average?